VBI Vaccines (NASDAQ:VBIV) Stock Passes Below Two Hundred Day Moving Average of $0.60

VBI Vaccines Inc. (NASDAQ:VBIV)’s share price crossed below its 200-day moving average during trading on Wednesday . The stock has a 200-day moving average of $0.60 and traded as low as $0.06. VBI Vaccines shares last traded at $0.07, with a volume of 28,280,883 shares trading hands.

Wall Street Analysts Forecast Growth

Separately, StockNews.com initiated coverage on shares of VBI Vaccines in a research report on Thursday. They set a “sell” rating for the company.

VBI Vaccines Stock Down 56.8 %

The firm’s fifty day moving average price is $0.55 and its 200-day moving average price is $0.59.

VBI Vaccines (NASDAQ:VBIV) last posted its earnings results on Wednesday, May 15th. The biopharmaceutical company reported ($0.55) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.53) by ($0.02). VBI Vaccines had a negative net margin of 881.79% and a negative return on equity of 525.42%. The business had revenue of $1.21 million during the quarter, compared to analysts’ expectations of $2.85 million.

VBI Vaccines Company Profile

VBI Vaccines Inc, a commercial-stage biopharmaceutical company, develops and sells vaccines to treat immuno-oncology and infectious disease. It offers Sci-B-Vac, a prophylactic hepatitis B (HBV) vaccine. The company also develops VBI-2601, a protein based immunotherapeutic candidate for the treatment of chronic HBV infection; VBI-1901, a glioblastoma vaccine immunotherapeutic candidate, which is in Phase I/IIa clinical study to treat solid tumors; VBI-1501, a prophylactic cytomegalovirus vaccine candidate that has completed Phase I clinical trial; and VBI-2501 that is in preclinical trial to treat Zika virus.